Advocate Clinical Laboratories
Every Sample is a Life™

Test Bulletin

October 2025

Additional Allele Detection of Dihydropyrimidine Dehydrogenase (DPYD) (Test Order Code LAB12430)

Effective Wednesday, October 15, 2025, ACL Laboratories added detection of eight (8) additional alleles to the current testing for dihydropyrimidine dehydrogenase (DPYD) (Test Order Code LAB12430). This update allows testing of all current Tier 1 and Tier 2 variants identified by the AMP/CPIC guidelines. Please see table for reference of all alleles detected.

Clinical Indication: The DPYD gene encodes dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme for fluoropyrimidine catabolism. Reduced activity of DPD results in reduced clearance and accumulation of 5-fluorouracil. The fluoropyrimidine drugs 5-fluorouracil and capecitabine are widely used in the treatment of solid tumors including colorectal and breast cancer, and cancers of the digestive tract. In individuals with reduced DPD activity, treatment with these drugs can lead to increased levels of 5-fluorouracil cause profound dose-related toxicities, such as severe digestive tract effects, neutropenia, and hand-foot syndrome. In some cases, these toxicities can lead to death.

Test Method: This test will be performed by ACL Laboratories using a laboratory developed test method based on PCR and mass spectrometry.

Specimen Requirements: One pink (K2EDTA) 6.0 mL **OR** Two lavender (K2EDTA) 3.0 mL
OR One ORAcollect Dx Buccal Swab kit

Transport: 5.0 mL (minimum 1.0 mL) whole blood or buccal swab, refrigerated

Stability: Ambient: 3 days whole blood, 1 week ORAcollect swab; Refrigerated: 2 weeks whole blood, 2 weeks ORAcollect swab; Frozen: Unacceptable

Performed: Weekdays

Performing Sites: ACL Illinois Central Laboratory

Reporting Time: 7 days

Allele	Clinical Functional Status	AMP/CPIC Tier
Reference (*1)	Normal function	
c.1905+1G>A (*2A)	Nonfunctional	1
c.1679T>G (*13)	Nonfunctional	1
c.2846A>T	Decreased function	1
c.1129-5923C>G	Decreased function	1
c.1129-5923C>G, c.1236G>A (HapB3)	Decreased function	1
c.557A>G	Decreased function	1
c.868A>G	Decreased function	1
c.2279C>T	Decreased function	1
c.299_302del (c.295_298delTCAT) (*7)	Nonfunctional	2
c.703C>T (*8)	Nonfunctional	2
c.1314T>G	Decreased function	2
c.1475C>T	Nonfunctional	2
c.1774C>T	Nonfunctional	2
c.2639G>T	Nonfunctional	2

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 10/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer
CM-HB-2507a

New Test Method for Hemochromatosis Mutation Detection (Test Order Code LAB8814)

Effective Wednesday, October 15, 2025, ACL Laboratories implemented a new test method for Hemochromatosis Mutation Detection (Test Order Code LAB8814). We will be moving from a PCR based method on an instrument that will no longer be supported by the vendor to a Mass Spectrometry based method. This new test method will continue to report the genotypes for C282Y and H63D and the report generated in EPIC will stay the same.

Test Method: This test will be performed by ACL Laboratories using a laboratory developed test method based on PCR and Mass Spectrometry.

Specimen Requirements: One lavender (K2EDTA) 3.0 mL OR One pink (K2EDTA) 6.0 mL

Transport: 3.0 mL (minimum 1.0 mL) whole blood, refrigerated

Stability: Ambient: 3 days; Refrigerated: 2 weeks; Frozen: Unacceptable

Performed: Weekdays

Performing Sites: ACL Illinois Central Laboratory

Reporting Time: Final within 7 days

If you have any questions, please contact:

ACL Molecular Pathology Laboratory at Rosemont (ph. 847-349-7182), or ACL Client Services (ph. 800-877-7016)

Order Change for Detection of Group A Streptococcus from Rectal, Perianal, Vaginal, and Vaginal/Rectal Specimens

ACL Laboratories made a recent change to the bacterial culture media used for the Streptococcus Group A (Streptococcus pyogenes), Bacterial Culture (Test Order code LAB9004). The media does not have any significant impact on the sensitivity or specificity of the culture, but it is easier to interpret and increases efficiency within the laboratory. However, the new media has not been validated for use with rectal, perianal, vaginal, and vaginal/rectal specimens. Therefore, these specimen types **should no longer be submitted** for testing using Test Order Code LAB9004.

Rectal, Perianal, Vaginal, and Vaginal/Rectal swab specimens may still be submitted to the ACL Laboratories microbiology lab for Group A Streptococcus culture. **Effective immediately,** these swab specimens should be submitted using the test "Single Bacterial Identification, Culture" (Test Order Code LAB9010). When ordering this test, providers must indicate that they are looking for "Group A Streptococcus". When using this order, specimens will be evaluated for the presence of Group A Streptococcus using the previously validated culture protocol. The cost, accuracy, and turnaround time will not change compared to when these specimens were tested using the "Streptococcus Group A (Streptococcus pyogenes), Bacterial Culture (Test Order Code LAB9004)" test.

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 10/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2507a

Effective Wednesday, October 15, 2025, the following send out assay was updated.

Coxsackie A Antibody		
	Current (Deactivated 10/15/2025)	**Replacement (Activated 10/15/2025)**
Test Name	Coxsackie A9 Antibody	Coxsackie A Antibodies (Serotypes 2, 4, 7, 9, 10 and 16), Serum
Test Order Code	LAB9478	LAB13110
Performing Lab	ARUP	ARUP
Specimen Type	Serum	2.0 mL Serum (1.0 mL minimum)
Collection container	Gold Gel	Red Top
Temperature	Refrigerated	Refrigerated
Stability	2 weeks	2 weeks
Methodology	Complement Fixation	Semi-Quantitative Complement Fixation
TAT	Final within 7 days	Final within 13 days

Effective Monday, October 20, 2025, the following send out assay will be updated.

Soluble Transferrin Receptor		
	Current (Deactivated 10/20/2025)	**Replacement (Activated 10/20/2025)**
Test Name	Soluble Transferrin Receptor	Soluble Transferrin Receptor, Serum or Plasma
Test Order Code	LAB9822	LAB13124
Performing Lab	ARUP	ARUP
Specimen Type	Serum	1.0 mL Serum (0.4 mL minimum)
Collection container	Gold Gel	Gold Gel
Temperature	Frozen	Frozen
Stability	1 month	1 month
Methodology	Quantitative Immunoturbidimetry	Quantitative Chemiluminescent Immunoassay (CLIA)
TAT	Final within 3 days	Final within 3 days

Effective Monday, October 20, 2025, the following send out assay will be updated.

Glucagon Specimen Collection Changes		
	Current (Deactivated 10/20/2025)	**Replacement (Activated 10/20/2025)**
Test Name	Glucagon	Glucagon
Test Order Code	LAB9556	LAB9556
Performing Lab	ARUP	ARUP
Specimen Type	Plasma	2.0 mL Plasma (0.5 mL minimum)
Collection container	One Protease Inhibitor tube (PPACK; Phe- Pro-Arg-chloromethylketone)	Pink (K2EDTA)
Temperature	Frozen	Frozen
Stability	3 months	1 month
Methodology	Quantitative Radioimmunoassay	Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
TAT	Final within 13 days	Final within 13 days

Created: 10/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2507a